Ra Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

rapharma.com

Founded Year

2008

Stage

Acq - P2P | Acquired

Total Raised

$77.56M

Valuation

$0000 

Revenue

$0000 

About Ra Pharmaceuticals

Ra Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the field of complement biology to bring accessible therapies to patients with rare diseases.

Ra Pharmaceuticals Headquarter Location

87 Cambridgepark Drive

Cambridge, Massachusetts, 02140,

United States

617-401-4060

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Ra Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Ra Pharmaceuticals in 1 CB Insights research brief, most recently on Oct 7, 2019.

Expert Collections containing Ra Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ra Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Ra Pharmaceuticals Patents

Ra Pharmaceuticals has filed 15 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Complement system
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/2/2020

5/25/2021

Complement system, Immune system, Clusters of differentiation, Immunology, Proteins

Grant

Application Date

1/2/2020

Grant Date

5/25/2021

Title

Related Topics

Complement system, Immune system, Clusters of differentiation, Immunology, Proteins

Status

Grant

Latest Ra Pharmaceuticals News

Civetta Therapeutics Appoints Jesse Smith, Ph.D. as CSO and Susan Ashwell, Ph.D. as SVP of Chemistry

May 17, 2022

- Appointments round out management team with expertise in drug discovery, development, and translational medicine- May 17, 2022 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--( BUSINESS WIRE )--Civetta Therapeutics, LLC, a biotechnology company focused on developing a pipeline of therapies that target beta-propeller proteins, today announced that it has strengthened its management team with the additions of Jesse Smith, Ph.D., as Chief Scientific Officer and Susan Ashwell, Ph.D., as Senior Vice President of Chemistry. “At Civetta, we realize that a great team is the foundation of everything we do, and the additions of Jesse and Sue position Civetta for further success at a pivotal point in our development,” said Christopher Roberts, Ph.D., Chief Executive Officer of Civetta. “We have made great strides advancing our lead drug discovery programs and mapping the known beta propellers to better understand their roles in driving disease. It’s an exciting time for the company as we move toward the clinic, and Jesse and Sue bring tremendous translational drug development experience across multiple therapeutic areas. They, like others on the Civetta leadership team, have firsthand experience leading programs into the clinic and beyond. I welcome them both and we look forward to their leadership.” “The team at Civetta has done great work building their novel platform and advancing their emerging pipeline of drugs that target the broad and previously unexploited protein family of beta propellers, which includes more than 600 potential targets,” said Dr. Smith. “This target-rich class of proteins represents an expansive opportunity to tackle protein-protein interactions in novel ways, while developing new treatments for patients in need across a range of diseases and therapeutic areas.” “Targeting beta propeller proteins has tremendous potential for a variety of reasons. They control the function of a diverse set of biological complexes associated with disease progression,” said Dr. Ashwell. “Because beta propellers can be readily drugged within a protein complex of interest, including using typical small molecule chemistry, they have the potential for more contextuality and specificity than conventional protein-targeting approaches. Civetta’s approach should dramatically expand the universe of tractable protein targets.” Jesse Smith, Ph.D., has over 20 years of experience advancing novel science, drug discovery, and therapeutics across the biotech and pharma industry. Prior to joining Civetta, he served as the Senior Vice President of Biology at REMIX Therapeutics, a Cambridge biotech focused on drugging RNA processing to target drivers of human disease, including cancer and neurodegeneration. While at REMIX, he played important roles in advancing the company’s lead programs and platform, resulting in $81 million in VC financing and in a recent pharma partnership with Janssen. As Vice President of Biology at Epizyme Pharmaceuticals, his team advanced to the clinic the first EZH2 inhibitor, which was recently approved in two oncology indications. While at Epizyme his team also advanced three additional oncology programs into the clinic in collaboration with GSK and Celgene. Jesse received his Ph.D. in Molecular Cancer Biology from Duke University Medical Center. Sue Ashwell, Ph.D., has worked in R&D in both biotech and pharma for more than 25 years, helping advance clinical candidates across a variety of target classes and therapeutic areas, including oncology, CNS disorders, inflammation, and immunology. Prior to joining Civetta, Dr. Ashwell was Head of Medicinal Chemistry at UCB, Cambridge (through the acquisition of Ra Pharmaceuticals) where she had multiple roles in group and project leadership and worked to coordinate external collaborations. Before her role at Ra Pharmaceuticals, Sue was a Senior Director in Chemistry at FORMA Therapeutics where she co-led the FT-2102 program, currently in clinical development. Sue joined FORMA from AstraZeneca where she was a member of both local and global cancer chemistry and cancer management teams responsible for setting strategy, portfolio delivery, and governance, including resource and budget allocation. Before her time at AstraZeneca, she was a medicinal chemist, group, and project leader with Wyeth-Ayerst Research. Sue received her Ph.D. in Organic Chemistry from the University of Newcastle upon Tyne, prior to conducting postdoctoral research at the University of Illinois at Chicago and Imperial College, London. About Civetta Civetta is a biotechnology company focused on the development of therapies that target beta-propeller domains to treat cancer and other diseases. The company was founded based on the pivotal insights into beta-propeller domains made by its founders , which helped elucidate beta-propeller domain functionality and their potential for therapeutic intervention in oncology as well as neurodegeneration, metabolic disease and other disease areas. Civetta is funded by Deerfield Management Company and is based in Cambridge, MA. For more information, please visit www.civettatherapeutics.com . Contacts

  • When was Ra Pharmaceuticals founded?

    Ra Pharmaceuticals was founded in 2008.

  • Where is Ra Pharmaceuticals's headquarters?

    Ra Pharmaceuticals's headquarters is located at 87 Cambridgepark Drive, Cambridge.

  • What is Ra Pharmaceuticals's latest funding round?

    Ra Pharmaceuticals's latest funding round is Acq - P2P.

  • How much did Ra Pharmaceuticals raise?

    Ra Pharmaceuticals raised a total of $77.56M.

  • Who are Ra Pharmaceuticals's competitors?

    Competitors of Ra Pharmaceuticals include Amplyx Pharmaceuticals, Alnylam Pharmaceuticals, SynDevRx, The Medicines Company, Milestone Pharmaceuticals and 12 more.

You May Also Like

Konova Logo
Konova

Konova offers anti-obesity drug development

S
SynDevRx

SynDevRx has developed a technology that increases the activity and safety of small molecule drugs using a conjugation technique. The company's technology increases a drug's therapeutic index by concentrating activity at the disease site. It provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile. SynDevRx's lead drug candidate SDX-7320 targets the oncology market, and inhibits MetAP2 - an enzyme which independent research has shown to be key to tumor growth, proliferation and metastasis.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

C
Cellogico

Cellogico Simulations Allow More Efficient Use Of Resources Through Highlighting Drug Targets With The Greatest Chance Of Success In The Early Stage Of Drug Development.

A
Auxeris Therapeutics

Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development

N
NeuroGenomeX

NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.